232. Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose: A Review.
Opioid use disorder (OUD) involves compulsive opioid use that causes substantial distress or impairment at work, school, or home. OUD, which is the third most prevalent substance use disorder worldwide, affected an estimated 3.7% of US adults (9 367 000) in 2022 and caused 53 774 deaths in the US in 2024. Medications for opioid use disorder (MOUD) reduce morbidity and mortality. Individuals with OUD also benefit from medications to treat opioid withdrawal and reverse acute opioid overdose.
238. Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial.
作者: Gail D'Onofrio.;Andrew A Herring.;Kathryn F Hawk.;Jeanmarie Perrone.;Ethan Cowan.;Ryan P McCormack.;James Dziura.;Abigail G Matthews.;Michael V Pantalon.;Patricia Owens.;Shara Martel.;Edouard Coupet.;Michele R Lofwall.;Sharon L Walsh.;E Jennifer Edelman.;Joseph E Carpenter.;Tania D Strout.;Michael R Baumann.;Erik Anderson.;Tyler W Barrett.;Alyrene Dorey.;Peter Taillac.;Gerald Cochran.;Cameron S Crandall.;Jason Wilson.;Jacob Manteuffel.;Jon B Cole.;Lauren K Whiteside.;Christopher Jones.;Elizabeth Samuels.;Kristen Huntley.;David A Fiellin.; .
来源: JAMA. 2026年335卷11期948-960页
Extended-release injectable buprenorphine may expand the reach of initiating medications for opioid use disorder in high-risk and hard-to-reach individuals who visit the emergency department (ED) and can be administered in low levels of withdrawal.
|